Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
Open Access
- 3 July 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 8 (1), 9997
- https://doi.org/10.1038/s41598-018-28337-6
Abstract
There is a relative lack of evidence about systemic treatments in patients with hepatocellular carcinoma (HCC) and moderate liver dysfunction (Child-Pugh B). In this multicenter study we retrospectively analyzed data from Child-Pugh B-HCC patients naïve to systemic therapies, treated with MC or best supportive care (BSC). To reduce the risk of selection bias, an inverse probability of treatment weighting approach was adopted. Propensity score was generated including: extrahepatic spread; macrovascular invasion; performance status, alphafetoprotein > 400 ng/ml, Child- Pugh score [B7 vs. B8–9]. We identified 35 MC-treated patients and 70 controls. Median overall survival was 7.5 [95% CI: 3.733–11.267]in MC-patients and 5.1 months [95% CI: 4.098–6.102] in the BSC group (p = 0.013). In patients treated with MC, median progression-free survival was 4.5 months (95% CI: 2.5–6.5). The univariate unweighted Cox regression showed a 42% reduction in death risk for patients on MC (95%CI: 0.370–0.906; p = 0.017). After weighting for potential confounders, death risk remained essentially unaltered. In the MC group, 12 patients (34.3%) experienced at least one adverse event, the most common of which were: fatigue (17.1%), hand-foot syndrome (8.5%), thrombocytopenia (8.5%), and neutropenia (5.7%). MC seems a safe option for Child-Pugh B-HCC patients. Its potential antitumour activity warrants prospective evaluations.This publication has 36 references indexed in Scilit:
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnnals of Oncology, 2013
- Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver functionClinical and Translational Oncology, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal of Cancer, 2012
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in ItalyJournal of Hepatology, 2011
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh scoreAlimentary Pharmacology & Therapeutics, 2011
- Metronomic chemotherapy: new rationale for new directionsNature Reviews Clinical Oncology, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver CirrhosisThe Oncologist, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and PerspectivesOncology Research and Treatment, 2007